The effect of interferon on the treatment of covid19 patients
- Conditions
- COVID19.
- Registration Number
- IRCT20160118026097N3
- Lead Sponsor
- Ghoum University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 60
Laboratory confirmation of Covid19 infection with reverse transcription polymerase chain reaction (RT-PCR) from any diagnostic sampling source
A new organ dysfunction related to Covid19
Being an adult
Intention to commit suicide (interfering with interferon (IFN) -b1b).
Sensitivity or sensitivity reaction to Lupinavir / Ritonavir or IFN-ß1b recombinant, including toxic epidermal necrolysis, Stevens-Johnson syndrome, erythema or angioedema syndrome.
ALT above 5 times normal
Use of drugs that are contraindicated with lopinavir / ritonavir and should not be substituted or discontinued during the study period, such as CYP3A inhibitors.
pregnancy.Eligible female participants are tested at gestational age before enrolling in the study for pregnancy.
HIV
Vulnerable groups
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Death within 30 days of hospitalization. Timepoint: every day. Method of measurement: View.
- Secondary Outcome Measures
Name Time Method Days without organ support (for example, supplemental O2, mechanical ventilation, dialysis and vasopressors). Timepoint: Time interval: 28 days. Method of measurement: View.;Results of RT-PCR in lower respiratory samples. Timepoint: Time interval: At the time of entering the study and one week after treatment and repetition every week until the negative sample of the period. Method of measurement: test.;Body Failure Assessment Scores (SOFA). Timepoint: Time frame: days 1, 3, 5, 7, 14 and 28). Method of measurement: check list.